Oestrogens and progestins for preventing and treating postpartum depression

Area of Science:

• Reproductive Endocrinology
• Perinatal Mental Health
• Pharmacology

Background:

• Postpartum depression (PPD) affects about 13% of women, with hormonal fluctuations during pregnancy and postpartum strongly suspected as a cause.
• Estrogens, progestins, and related compounds exhibit significant central nervous system activity at physiological levels.

Purpose of the Study:

• To evaluate the efficacy of estrogens and progestins in preventing and treating postpartum depression.
• To compare these hormonal interventions against placebo or standard care during the perinatal period.

Main Methods:

• Comprehensive search of major biomedical databases (Cochrane, MEDLINE, EMBASE, CINAHL) and secondary references.
• Inclusion of all randomized controlled trials (RCTs) assessing estrogen/progestin interventions versus placebo or standard care in women within one year postpartum.
• Data extraction and analysis by two independent reviewers, using relative risk and weighted mean difference.

Main Results:

• Two trials with 229 women met the criteria.
• Norethisterone enanthate (synthetic progestogen) given within 48 hours postpartum was linked to a higher risk of PPD.
• Estrogen therapy showed improved depression scores compared to placebo in women with severe depression.

Conclusions:

• Caution is advised when using synthetic progestogens postpartum due to increased PPD risk.
• The role of natural progesterone in PPD prevention/treatment requires further RCT investigation.
• Estrogen therapy may provide moderate benefits for severe PPD, but its preventative role needs more rigorous evaluation.